What lies ahead for the central nervous system stimulant drugs market? | Healthcare Asia Magazine
, APAC
Photo from Envato

What lies ahead for the central nervous system stimulant drugs market?

Third-generation drugs drive its expansion, though potential side effects could hinder further growth.

The global central nervous system (CNS) stimulant drugs market is projected to rise by $6.48b until 2027 at an estimated compound annual growth rate (CAGR) of 5.8%.

A report by Technavio revealed that the market is being driven by an increase in CNS disorders whilst witnessing a trend towards new-generation drugs.

“Third-generation anti-epileptic drugs, such as rufinamide, eslicarbazepine, retigabine, and lacosamide, have emerged. These drugs offer even fewer side effects and broader therapeutic ranges, leading to a higher uptake,” it said.

However, potential side effects may impede the market’s growth.

Medication for Attention-Deficit Hyperactivity Disorder (ADHD), such as methylphenidates are associated with issues involving heart and liver damage, strokes, and epilepsy amongst others.

Meanwhile, narcolepsy drugs at high doses, such as amphetamines, can potentially lead to brain injury and neurotoxicity.

“Additionally, stimulants are frequently abused, resulting in health risks such as cardiovascular complications, seizures, and structural brain changes,” the report added.

Overall, the market is experiencing notable growth in healthcare services related to child and adolescent psychiatry, sleep apnea, and other sleep disorders due to an increasing demand for effective treatments.

Moreover, the market prioritises expanding clinical coverage and addressing needs in CNS stimulant therapies, focusing on strategies such as collaborations, acquisitions, and product development.

 

EMC Healthcare dan InterSystems akan meluncurkan sistem rekam medis elektronik canggih di Indonesia

Sistem ini dilengkapi dengan dokumentasi otomatis dan kode berbasis AI.

Rumah sakit swasta di Filipina diminta berhati-hati akan pengeluaran

Klaim layanan kesehatan di negara ini diperkirakan meningkat 21% tahun ini.

KTPH melacak pasien dan peralatan secara real-time

Rumah sakit milik negara Singapura ini juga berencana menggunakan gelang RFID pasif untuk melacak lokasi pasien.

Sistem otomatis mengangkut instrumen bedah di Singapura

Sistem ini mengirimkan instrumen siap pakai langsung ke meja operasi.

Island Hospital menggunakan rehabilitasi berbasis data untuk mempercepat pemulihan

Teknologi ini menyesuaikan latihan pasien dan memberikan feedback secara real-time.

Rumah Sakit didesak menutup kesenjangan dalam layanan kesehatan perempuan

Investasi yang lebih baik dalam kesehatan perempuan dapat meningkatkan perekonomian global sebesar USD 1 triliun per tahun pada 2040.

NUHCS melatih lebih banyak ahli bedah untuk implantasi katup jantung yang kurang invasif

TAVI menargetkan kondisi yang sering dimulai dengan murmur jantung.